2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow melflufen: new trials by email Literature Review of melflufen trials Research Report on melflufen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma Melflufen, Dexamethasone, Daratumumab - Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma | Phase 3 | Terminated | Oncopeptides AB | 54 | 2020-12-21 | 2023-06-08 |
| A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide Melflufen, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Terminated | Oncopeptides AB | 495 | 2017-06-12 | 2024-01-30 |
Multiple Myeloma (2)
Oncopeptides AB (2)
Czechia (2) · Greece (2) · Norway (2) · Poland (2) · Russia (2) · Spain (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Denmark (1) · Estonia (1) · France (1) · Georgia (1) · Germany (1) · Hungary (1)
PMID 35032434, PMID 37355418, PMID 37646657, PMID 37646660, PMID 38426292, PMID 41437395
2019 (1)